September 29th 2025
Vaccines for respiratory syncytial virus were found both safe and effective across 100,000 participants and, critically, for older adults and infants.
September 25th 2025
Your daily dose of the clinical news you may have missed.
September 9th 2025
New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.
September 5th 2025
A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.
Sanofi's Chlamydia Vaccine Granted FDA Fast Track Designation
The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.
Improved HPV Vaccination Coverage May Help Prevent Noncervical Cancers in People with HIV
CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.
US Adult Vaccination Snapshots: Current Coverage, Trends, and Concerns
Get the latest immunization updates, data on racial disparities, and practical guidance for clinical practice, here.
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
FDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care Use
The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.
FDA Approves GSK's Pentavalent Meningococcal Vaccine Penmenvy
The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.
2025 GOLD Report on COPD Addresses Cardiovascular Risk in New Section: MeiLan Han, MD, MS, Highlights Rationale
Cardiovascular comorbidities in adults with COPD are linked to poor outcomes including reduced QoL, increased hospitalizations, and greater risk of mortality, Han explains.
Vaccine Hesitancy in the Chronic Conditions Community: New Survey Findings
People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.
Sen-Jam Pharmaceutical Reports Preliminary Phase 2 Results for SJP-002C in COVID-19 Treatment
The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.
New COVID-19 Vaccination Guidance for Older Adults & High-Risk Groups: A Conversation with NFID Medical Director Robert Hopkins, Jr, MD
Guidance from the Advisory Committee on Immunization Practices on best practices for COVID-19 vaccination continues to evolve, Hopkins explained.
FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning
The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.
Vaccination Information and Educational Resources from the National Foundation for Infectious Diseases
Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.
NFID Medical Director Highlights ACIP Rationale for Lowering Age for Pneumococcal Vaccination
Under risk-based guidelines, less than 30% of eligible adults are vaccinated against pneumococcal disease, said Robert Hopkins, Jr, MD. More details, here.
CDC Adds Heplisav-B to Recommendations for HepB Vaccination During Pregnancy
The addition, based on an approved update to labeling, expands to 4 the recommended vaccination options that health care professionals can offer to pregnant people.
Sanofi Investigational COVID-19/Influenza Combination Vaccines Granted FDA Fast-Track Designation
The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.
US Adults Lagging in Flu, COVID-19, and RSV Vaccination: Daily Dose
Pandemic Medical Misinformation Has Not Prompted Disciplinary Action: Daily Dose
Pandemic Medical Misinformation Has Not Prompted Disciplinary Action, Study Reveals
Little action has been taken by state medical boards against clinicians who spread unsubstantiated claims about COVID-19, vaccines, or other pandemic-related topics.
FDA Lifts Clinical Hold on Novavax’s COVID-19-Influenza Combination Vaccine
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.
November Issue of Patient Care Online Digital Edition is Now Live
Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.
Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose
Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose
Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals
CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.
ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years
The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.
FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions
Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.
FDA Updates Flublok Label with Safety Data for Pregnant Individuals
The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.
Pfizer-BioNTech COVID-19 Vaccine May Reduce Risk of Long COVID in Older Adults
IDWeek 2024: Older adults vaccinated with BNT162b2 (Comirnaty) had approximately half the odds of developing long COVID vs unvaccinated adults, according to new data.
IDWeek 2024: Novavax Reports Positive Data for Novel Influenza and Flu-COVID-19 Combination Vaccines
IDWeek2024: The nanoparticle influenza vaccine and combination flu-Covid-19 shot produced immunogenicity comparable to or higher than comparator vaccines.
IDWeek 2024: Merck’s 21-Valent Pneumococcal Vaccine Shows Positive Immune Responses in At-Risk Adults
V116 (CAPVAXIVE™) covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases in adults aged 50 years and older.